EGFR and non-small cell lung carcinoma: Amivantamab, carboplatin, and pemetrexed was approved by the FDA as a combination for advanced NSCLC patients with EGFR exon 19 deleterious or exon 21 L858R mutation after EGFR TKI failure driven by these results.122